Business
Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results
Surgical Aesthetics revenue increased approximately 38% year-over-year in the fourth quarter of 2025, including an increase of approximately 51% in the U.S. following the launch of AYONCLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported preliminary revenue results for the fourth quarter and full year
About this update from Apyx Medical Corporation
[{"type":"image","alt":"Apyx Medical Corporation","displaySize":"","headline":null,"caption":"Apyx Medical Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/f776ee7f25241f6a4c93b21ba8aff893"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WNW7RVUw1wUG.ea_dTVO0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f776ee7f25241f6a4c93b21ba8aff893","width":300,"height":157}},"lazy":false},{"type":"text","content":"Surgical Aesthetics revenue increased approximately 38% year-over-year in the fourth quarter of 2025, including an increase of approximately 51% in the U.S. following the launch of AYON","length":185,"tagName":"p"},{"type":"text","content":"CLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2025.","length":340,"tagName":"p"},{"type":"text","content":"Preliminary Fourth Quarter 2025 Revenue Summary:","length":48,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year.","length":147,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Surgical Aesthetics revenue is expected to be in the range of approximately $16.6 to $16.8 million, representing an increase of approximately 38% year-over-year.","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"OEM revenue is expected to be approximately $2.4 million, representing an increase of approximately 13% year-over-year.","length":119,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":280,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":427,"olType":false},{"type":"text","content":"Preliminary Full Year 2025 Revenue Summary:","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue is expected to be in the range of approximately $52.7 to $52.9 million, representing an increase of approximately 10% year-over-year.","length"...